Oragenics

OGEN · NYSE American

$0.434+$0.012 (+2.84%)TodayMarket closed · Oct 20, 8:00 PM ET

Prev close $0.422

Latest news

Press releaseSep 16, 8:30 AM ETGlobe Newswire
Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum
NewsAug 28, 4:28 PM ET
Oragenics Advances Phase IIa Trial With 9 Participants Dosed; Recieved NYSE American Non Compliance Letter, Has 45 Days From Receipt Of The Deficiency Letter Within Which To Submit A Plan To Regain Compliance With The Continued Listing Standards
Press releaseAug 28, 4:25 PM ETGlobe Newswire
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
Press releaseJul 7, 8:30 AM ETGlobe Newswire
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
Press releaseMay 19, 8:45 AM ETGlobe Newswire
Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21
Press releaseMay 18, 8:30 AM ETGlobe Newswire
ORAGENICS PROVIDES INVESTOR UPDATE
Press releaseMay 5, 8:30 AM ETGlobe Newswire
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
Press releaseApr 20, 9:00 AM ETGlobe Newswire
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
Press releaseApr 13, 8:30 AM ETGlobe Newswire
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
Press releaseMar 25, 6:30 PM ETGlobe Newswire
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
Press releaseMar 17, 8:30 AM ETGlobe Newswire
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
Press releaseMar 12, 8:30 AM ETGlobe Newswire
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
Press releaseMar 11, 8:30 AM ETGlobe Newswire
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION
Press releaseMar 10, 8:30 AM ETGlobe Newswire
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia
Press releaseNov 12, 8:30 AM ETBusiness Wire
Oragenics Q3 2025 Shareholder Update
Press releaseOct 21, 8:00 AM ETBusiness Wire
Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
Press releaseOct 7, 8:30 AM ETBusiness Wire
Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development
NewsJul 1, 1:05 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsJul 1, 12:51 PM ETAvi Kapoor
Nasdaq Dips 150 Points; US ISM Manufacturing PMI Rises In June
NewsJul 1, 10:08 AM ETAvi Kapoor
US Stocks Mixed; Dow Gains Over 50 Points
NewsJul 1, 8:07 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
NewsJul 1, 5:23 AM ETAvi Kapoor
Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
NewsJun 27, 5:05 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
NewsJun 2, 10:16 AM ETAvi Kapoor
Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings
NewsMay 28, 1:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsMay 5, 5:05 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
NewsApr 2, 5:05 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsFeb 5, 9:44 AM ETAvi Kapoor
US Stocks Mixed; Walt Disney Posts Upbeat Earnings
NewsOct 8, 6:36 AM ETAvi Kapoor
Why DocuSign Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
NewsSep 4, 1:32 PM ETAvi Kapoor
Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings
NewsSep 4, 12:22 PM ETHenry Khederian
Why Oragenics (OGEN) Stock Is Getting Hammered
NewsSep 4, 10:06 AM ETAvi Kapoor
US Stocks Mixed; Trade Gap Widens In July
NewsSep 4, 6:39 AM ETAvi Kapoor
Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Press releaseAug 9, 9:00 AM ETPRNewswire
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum

Oragenics Advances Phase IIa Trial With 9 Participants Dosed; Recieved NYSE American Non Compliance Letter, Has 45 Days From Receipt Of The Deficiency Letter Within Which To Submit A Plan To Regain Compliance With The Continued Listing Standards

Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update

Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling

Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21

ORAGENICS PROVIDES INVESTOR UPDATE

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

ORAGENICS FILES ANNUAL REPORT ON FORM 10-K

ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION

Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

Oragenics Q3 2025 Shareholder Update

Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

12 Health Care Stocks Moving In Tuesday's Intraday Session

Nasdaq Dips 150 Points; US ISM Manufacturing PMI Rises In June

US Stocks Mixed; Dow Gains Over 50 Points

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Friday's After-Market Session

Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

US Stocks Mixed; Walt Disney Posts Upbeat Earnings

Why DocuSign Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket

Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings

Why Oragenics (OGEN) Stock Is Getting Hammered

US Stocks Mixed; Trade Gap Widens In July

Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032